Answer
Crizotinib inhibits ALK and its oncogenic variants (ALK fusion events and selected ALK mutations), hepatocyte growth factor receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON) receptor tyrosine kinases.
Sources for this answer
- Xalkori 200mg hard capsulePfizer Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 37Document updated
Sources checked